Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Chemoprevention of Rat Mammary Carcinogenesis by Apiaceae Spices.

Aqil F, Jeyabalan J, Munagala R, Ravoori S, Vadhanam MV, Schultz DJ, Gupta RC.

Int J Mol Sci. 2017 Feb 16;18(2). pii: E425. doi: 10.3390/ijms18020425.

2.

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Minasian LM, Tangen CM, Wickerham DL.

Semin Oncol. 2015 Oct;42(5):748-63. doi: 10.1053/j.seminoncol.2015.07.006. Epub 2015 Jul 10. Review.

3.

Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.

Tzeng HE, Muo CH, Chen HT, Hwang WL, Hsu HC, Tsai CH.

BMC Musculoskelet Disord. 2015 May 20;16:123. doi: 10.1186/s12891-015-0580-8.

4.

Tamoxifen and Src kinase inhibitors as neuroprotective/neuroregenerative drugs after spinal cord injury.

Salgado IK, Torrado AI, Santiago JM, Miranda JD.

Neural Regen Res. 2015 Mar;10(3):385-90. doi: 10.4103/1673-5374.153685. Review.

5.

Biomimetic receptors for bioanalyte detection by quartz crystal microbalances - from molecules to cells.

Latif U, Qian J, Can S, Dickert FL.

Sensors (Basel). 2014 Dec 5;14(12):23419-38. doi: 10.3390/s141223419.

6.

Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.

Maximov PY, McDaniel RE, Fernandes DJ, Bhatta P, Korostyshevskiy VR, Curpan RF, Jordan VC.

J Natl Cancer Inst. 2014 Sep 24;106(10). pii: dju283. doi: 10.1093/jnci/dju283. Print 2014 Oct.

7.

Tamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: their antioxidant effect and role of estrogen receptor alpha.

Mosquera L, Colón JM, Santiago JM, Torrado AI, Meléndez M, Segarra AC, Rodríguez-Orengo JF, Miranda JD.

Brain Res. 2014 May 2;1561:11-22. doi: 10.1016/j.brainres.2014.03.002. Epub 2014 Mar 15.

8.

Cancer-associated bone disease.

Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Glüer CC, Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, de Villiers TJ, El Hajj Fuleihan G; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease..

Osteoporos Int. 2013 Dec;24(12):2929-53. doi: 10.1007/s00198-013-2530-3. Epub 2013 Oct 22. Review.

9.

Sex hormone levels and risk of breast cancer with estrogen plus progestin.

Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR.

J Natl Cancer Inst. 2013 Oct 2;105(19):1496-503. doi: 10.1093/jnci/djt243. Epub 2013 Sep 16.

10.

Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.

Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF, Decker DA.

J Oncol Pract. 2012 May;8(3):144-8. doi: 10.1200/JOP.2011.000352. Epub 2012 Feb 7.

11.

Recommendations for raloxifene use in daily clinical practice in the Swiss setting.

Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhäuser M.

Eur Spine J. 2012 Dec;21(12):2407-17. doi: 10.1007/s00586-012-2404-y. Epub 2012 Jun 28. Review.

12.

Evaluation of a luciferase-based reporter assay as a screen for inhibitors of estrogen-ERα-induced proliferation of breast cancer cells.

Andruska N, Mao C, Cherian M, Zhang C, Shapiro DJ.

J Biomol Screen. 2012 Aug;17(7):921-32. doi: 10.1177/1087057112442960. Epub 2012 Apr 12.

13.

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V.

Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. doi: 10.1158/1940-6207.CAPR-11-0154. Epub 2011 Sep 1.

14.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

15.

Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study.

Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, Henderson BE, Le Marchand L, Kolonel LN, Goodman MT.

Endocr Relat Cancer. 2010 Feb 18;17(1):125-34. doi: 10.1677/ERC-09-0211. Print 2010 Mar.

16.

Progress in osteoporosis and fracture prevention: focus on postmenopausal women.

Saag KG, Geusens P.

Arthritis Res Ther. 2009;11(5):251. doi: 10.1186/ar2815. Epub 2009 Oct 14. Review.

17.

Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial.

Cauley JA, LaCroix AZ, Robbins JA, Larson J, Wallace R, Wactawski-Wende J, Chen Z, Bauer DC, Cummings SR, Jackson R.

Osteoporos Int. 2010 Jan;21(1):167-77. doi: 10.1007/s00198-009-0953-7. Epub 2009 May 13.

19.

Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk.

Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K.

J Natl Cancer Inst. 2009 Mar 18;101(6):384-98. doi: 10.1093/jnci/djp018. Epub 2009 Mar 10. Review.

20.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel VG.

Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.

Supplemental Content

Support Center